中成药2024,Vol.46Issue(3) :795-802.DOI:10.3969/j.issn.1001-1528.2024.03.013

壮药双路通脑方对脑缺血再灌注损伤大鼠神经元凋亡的影响

Effects of Zhuangyao Shuanglu Tongnao Formula on neuronal apoptosis of rats with ischemia-reperfusion induced injury

翟阳 莫雪妮 滕红丽 胡跃强 郑光珊 马威 杨鹏 梅小平 邹敏 王凯华
中成药2024,Vol.46Issue(3) :795-802.DOI:10.3969/j.issn.1001-1528.2024.03.013

壮药双路通脑方对脑缺血再灌注损伤大鼠神经元凋亡的影响

Effects of Zhuangyao Shuanglu Tongnao Formula on neuronal apoptosis of rats with ischemia-reperfusion induced injury

翟阳 1莫雪妮 2滕红丽 3胡跃强 4郑光珊 3马威 2杨鹏 5梅小平 6邹敏 7王凯华3
扫码查看

作者信息

  • 1. 广西国际壮医医院脑病科,广西 南宁 530200;广西中医药大学,广西 南宁 530200
  • 2. 广西中医药大学,广西 南宁 530200
  • 3. 广西国际壮医医院脑病科,广西 南宁 530200
  • 4. 广西中医药大学第一附属医院脑病科,广西 南宁 530200
  • 5. 广西国际壮医医院科技部,广西 南宁 530200
  • 6. 广西国际壮医医院内分泌代谢病科,广西 南宁 530200
  • 7. 广西国际壮医医院儿科,广西 南宁 530200
  • 折叠

摘要

目的 基于氧化应激和炎症反应探讨壮药双路通脑方对脑缺血再灌注损伤大鼠神经元凋亡的影响.方法 将大鼠随机分为假手术组,模型组,壮药双路通脑方低、中、高剂量组(9.0、18.0、36.0 g/kg),依达拉奉组(3.0 mg/kg),每组18 只,采用线栓法构建大脑中动脉闭塞/再灌注模型以模拟脑缺血再灌注损伤,给予相应药物干预6d,采用Zeal Longa评分法对大鼠进行神经功能缺损评分,TTC染色检测脑梗死面积,HE染色和TUNEL染色检测脑组织缺血半暗带海马CA1 区神经元病理损伤和细胞凋亡情况,试剂盒检测脑组织SOD活性和GSH、MDA、IL-6、IL-1β、TNF-α水平,Western blot法检测大鼠脑组织Bax、Bcl-2、caspase-3、cleaved-caspase-3、TLR4、NF-κB p65、Nrf2、HO-1蛋白表达.结果 与模型组比较,壮药双路通脑方中、高剂量组和依达拉奉组大鼠神经功能缺损评分,脑梗死率,神经元凋亡率,脑组织缺血半暗带IL-6、IL-1β、TNF-α、MDA水平,Bax、TLR4 蛋白表达,cleaved-caspase-3/caspase-3、p-NF-κB p65/NF-κB p65 比值降低(P<0.05),GSH 水平、SOD 活性和 Bcl-2、Nrf2、HO-1 蛋白表达升高(P<0.05).结论 壮药双路通脑方可抑制氧化应激和炎症反应,抑制神经元凋亡,改善神经功能,减轻脑缺血再灌注损伤大鼠的脑损伤,其机制可能与抑制TLR4/NF-κB信号通路和激活Nrf2/HO-1信号通路有关.

Abstract

AIM To investigate the effects of Zhuangyao Shuanglu Tongnao Formula on neuronal apoptosis in rats with cerebral ischemia-reperfusion injury based on the study of oxidative stress and inflammatory response.METHODS The rats were randomly divided into the sham operation group,the model group,the edaravone group(3.0 mg/kg),the low,medium and high dose groups(9.0,18.0,36.0 g/kg)of Zhuangyao Shuanglu Tongnao Formula,with 18 rats in each group.The middle cerebral artery occlusion/reperfusion was conducted by thread embolism method to simulate cerebral ischemia reperfusion injury in rats followed by 6 days corresponding drugs administration.Subsequently,the rats had their neurological function deficit scored by Zeal Longa scoring method;their sizes of cerebral infarction areas measured by TTC staining;their pathological damage and apoptosis of neurons in hippocampal CA1 area of ischemic penumbra of the brain tissue detected by HE staining and TUNEL staining;their SOD activity and levels of GSH,MDA,IL-6,IL-1β,TNF-α in brain tissue detected by kits;and their protein expressions of Bax,Bcl-2,caspase-3,cleaved-capase-3,TLR4,NF-κB p65,Nrf2,HO-1 in rat brain tissue determined by Western blot.RESULTS Compared with the model group,the groups intervened with edaravone,medium and high dose of Zhuangyao Shuanglu Tongnao Formula displayed improvements in the scores of nerve function defects,the rate of cerebral infarction,the rate of neuronal apoptosis,the levels of IL-6,IL-1β,TNF-α and MDA in the ischemic penumbra of brain tissues,the protein expressions of Bax and TLR4,the ratio of cleaved-capase-3/caspase-3 and p-NF-κB p65/NF-κB p65(P<0.05),the levels of GSH,the activity of SOD and the protein expressions of Bcl-2,Nrf2 and HO-1(P<0.05).CONCLUSION Being an inhibitor of oxidative stress and inflammatory response,Zhuangyao Shuanglu Tongnao Formula can alleviate brain injury in rats with cerebral ischemia reperfusion injury through the inhibition of neuronal apoptosis and improvement of neural function mediated by the inhibition of TLR4/NF-κB signal pathway and activation of Nrf2/HO-1 signal pathway.

关键词

壮药双路通脑方/缺血性脑卒中/脑缺血再灌注损伤/凋亡/氧化应激/炎症反应/TLR4/NF-κB信号通路/Nrf2/HO-1信号通路

Key words

Zhuangyao Shuanglu Tongnao Formula/ischemic stroke/cerebral ischemia-reperfusion injury/apoptosis/oxidative stress/inflammatory response/TLR4/NF-κB signaling pathway/Nrf2/HO-1 signaling pathway

引用本文复制引用

基金项目

国家自然科学基金(81874453)

广西自然科学基金(2020JJA140299)

广西自然科学基金(2021JJB140540)

中医药自筹经费科研课题(2021)(20210360)

广西中医脑病临床研究中心项目(桂科AD20238028)

广西中医药大学"岐黄工程"高层次人才团队培育项目(第二批)(2021008)

广西壮族自治区中医药重点学科建设项目(GZXK-Z-20-62)

广西中医基础研究重点实验室项目(K201255801)

广西国际壮医医院院级课题(GZ2021007)

出版年

2024
中成药
国家食品药品监督管理局,信息中心中成药信息站,上海中药行业协会

中成药

CSTPCD北大核心
影响因子:1.217
ISSN:1001-1528
参考文献量24
段落导航相关论文